Attachment 2. Extract from the Clinical Evaluation Report ...

The FDA submission was not consistent with the Note for Guidance and should therefore be considered of less direct relevance in the Australian context. The primary efficacy endpoint for the FDA submission was the . ... nearly all subjects received concomitant medications of various types, as expected in an older population. Thus, the safety ... ................
................